Age-dependent dopaminergic dysfunction in Nurr1 knockout mice
暂无分享,去创建一个
Tianhong Pan | W. Le | T. Pan | Weidong Le | Chuantao Jiang | Xinhua Wan | Yi He | Chuantao Jiang | Yi He | Xinhua Wan
[1] Nicolas Lapointe,et al. Rotenone induces non‐specific central nervous system and systemic toxicity , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] E. Richfield,et al. Age‐related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype , 2003, The European journal of neuroscience.
[3] W. Le,et al. Mutant genes responsible for Parkinson's disease. , 2004, Current opinion in pharmacology.
[4] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[5] S. Appel,et al. Use of [3H]-GBR12935 to measure dopaminergic nerve terminal growth into the developing rat striatum. , 1992, Brain research. Developmental brain research.
[6] P. Jenner,et al. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. , 2003, Parkinsonism & related disorders.
[7] M. Palkovits,et al. Dopamine Biosynthesis Is Selectively Abolished in Substantia Nigra/Ventral Tegmental Area but Not in Hypothalamic Neurons in Mice with Targeted Disruption of the Nurr1 Gene , 1998, Molecular and Cellular Neuroscience.
[8] O. Conneely,et al. Selective Agenesis of Mesencephalic Dopaminergic Neurons in Nurr1-Deficient Mice , 1999, Experimental Neurology.
[9] G. Miller,et al. Detection of Behavioral Impairments Correlated to Neurochemical Deficits in Mice Treated with Moderate Doses of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 2002, Experimental Neurology.
[10] David J Brooks,et al. Plasticity of the nigropallidal pathway in Parkinson's disease , 2003, Annals of neurology.
[11] David W. Miller,et al. Co‐ordinate transcriptional regulation of dopamine synthesis genes by α‐synuclein in human neuroblastoma cell lines , 2003, Journal of neurochemistry.
[12] V. Sossi,et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.
[13] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[14] C. Bruce,et al. Chaperone Suppression of a-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2002 .
[15] Joseph Jankovic,et al. Role of nitric oxide in rotenone‐induced nigro‐striatal injury , 2003, Journal of neurochemistry.
[16] M. Youdim,et al. Mechanism of 6-hydroxydopamine neurotoxicity. , 1997, Journal of neural transmission. Supplementum.
[17] D. Twelves,et al. Systematic review of incidence studies of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[18] B. Hoffer,et al. Elevated locomotor activity without altered striatal dopamine contents in Nurr1 heterozygous mice after acute exposure to methamphetamine , 2003, Behavioural Brain Research.
[19] B. O’Malley,et al. Identification of a new brain-specific transcription factor, NURR1. , 1992, Molecular endocrinology.
[20] E. López-Martín,et al. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism , 1998, Journal of Neuroscience Methods.
[21] H J Gundersen,et al. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[22] M. Smidt,et al. Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons , 2003, The European journal of neuroscience.
[23] George Paxinos,et al. The Mouse Brain in Stereotaxic Coordinates , 2001 .
[24] B. Långström,et al. Regulation of dopaminergic activity in early Parkinson's disease , 1999, Annals of neurology.
[25] D B Calne,et al. Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. , 1991, Archives of neurology.
[26] B. Lipska,et al. Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity , 2002, Behavioural Brain Research.
[27] B J Hoffer,et al. Dopamine neuron agenesis in Nurr1-deficient mice. , 1997, Science.
[28] J. Jankovic,et al. Reduced Nurrl Expression Increases the Vulnerability of Mesencephalic Dopamine Neurons to MPTP‐Induced Injury , 1999, Journal of neurochemistry.
[29] Sarah J Tabrizi,et al. Models of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[30] E. Cochran,et al. Age‐related decreases in Nurr1 immunoreactivity in the human substantia nigra , 2002, The Journal of comparative neurology.
[31] B. Joseph,et al. Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. , 2003, Experimental cell research.
[32] J. Eells,et al. Dopamine neurons heterozygous for the Nurr1‐null allele have reduced survival in vitro , 2002 .
[33] T. Dawson,et al. Molecular Pathways of Neurodegeneration in Parkinson's Disease , 2003, Science.
[34] M. Smidt,et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[35] W. Gibb,et al. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. , 1991, Journal of neurology, neurosurgery, and psychiatry.